300+ investors in your industry, stage, and region Get
Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Puerto Rico
Oman
Poland
Guernsey
Cameroon
Colombia
China
Armenia
Czech Republic
Costa Rica
Marshall Islands
Kuwait
Malta
Luxembourg
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Seychelles
Moldova
Paraguay
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
LSK Investment, VC Fund

LSK Investment

VC Fund

Seoul, South Korea

LSK Investment is a Korean venture capital firm that provides long-term capital and management support to venture enterprises. The firm was founded in 2016 and is based in Seoul, Korea.

Total investments:
45
Last investment:
Lead investor:
11%
Fund size:
$15M
Last fund:

Last updated:

Industries LSK Investment invests in

BiotechnologyMedicalHealth CarePharmaceuticalBiopharma

Stages LSK Investment invests in

Series ASeries BSeries CVenture - Series UnknownSeed

Countries LSK Investment invests in

South KoreaUnited States

Round sizes

Series A $1.6M–$14MSeries B $8.3M–$16MSeries C $3.2M–$46M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$1.6M–$14M
Series B
$8.3M–$16M
Series C
$3.2M–$46M

Investment Focus

Industry

  • Biotechnology 22 (49%)
  • Medical 17 (38%)
  • Health Care 15 (33%)
  • Pharmaceutical 10 (22%)
  • Biopharma 9 (20%)
See all 38 industries →

Stage

  • Series A 19 (42%)
  • Series B 12 (27%)
  • Series C 5 (11%)
  • Venture - Series Unknown 4 (9%)
  • Seed 3 (7%)
See all 6 stages →

Country

  • South Korea 37 (82%)
  • United States 1 (2%)

Team

NameTitleInvestmentsLinksEmail
Lee Myung-kwon Managing Director
Managing Director Total investments: 1 Find email

Investments

CompanyDescriptionRoundLinks
IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. $29.5M / Series C / Oct 14, 2025
MBD MBD
MBD is a biotechnology company that specializes in 3D cell culture platforms. $11.9M / Series C / Aug 14, 2025
Trioar is a biotechnological research company that manufacture pharmaceutical products and drugs. $16.2M / Series B / Jul 17, 2025
Medi Builder operates as a Medical Accelerator Management Services Organization (MSO), functioning as a non-hospital business agency similar to its subsidiaries, the special-purpose medical companies (SMCs). However, there are significant differences between SMCs and the MSO in terms of capacity for acceleration, growth potential, and exit plans. $10.3M / Series B / Jun 05, 2025
NeuroXT develops software for precision diagnosis that predicts molecular pathology values. It uses magnetic resonance imaging (MRI) data to assess the effects and adverse reactions of specific drugs, supporting evaluation of patient suitability. The system applies image analysis methods to inform treatment decisions for degenerative braindiseases. Series A / Mar 10, 2025
Special Touch Nursing Services provides in-home nursing care, including health assessments, medication management, and non-medical assistance such as personal care, transportation, and household support. The company also offers licensed case management services to assess needs, coordinate care plans, and advocate on behalf of clients and families.Services are delivered by registered nurses, licensed social workers, nursing assistants, and caregivers to support independence and well-being for seniors and disabled individuals. $1.3M / Seed / Nov 20, 2024
Avelos Therapeutics is a precision medicine company in the clinical stage that finds, creates, and sells targeted therapeutics. $12.4M / Series B / May 02, 2024
Refeely is a refill-focused packaging company that offers B2B packaging solutions using refillable paper cartons for products. The company develops eco-friendly refill products and paper-based packaging system. $742.8K / Seed / Mar 29, 2024
Surginex is a biological drug development company that offers molecular biology, genetics, physical, and chemical analysis services. $6.3M / Series B / Mar 28, 2024
Surginex is a biological drug development company that offers molecular biology, genetics, physical, and chemical analysis services. $6.3M / Mar 27, 2024
See all 45 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Hospitality
Video Games
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
Energy
SaaS
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Wellness
Education
Medical Device
Automotive
eSports
Sports
Legal
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Medical
Web3
Theatre
Recruiting
Crowdfunding
Infrastructure
Venture Capital
Beauty
Fashion
Social
Celebrity
LGBT
Climate
Cannabis
Wine and Spirits
Mobile Apps
Life Science
Food and Beverage
Publishing
Art
Music
Real Estate
Sporting Goods
FinTech
Finance
Digital Media
Manufacturing
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Sustainability
Proptech
Hardware
Impact
Transportation
Biotech
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
Japan
South Korea
Singapore
Burkina Faso
LATAM
Brazil
Africa
Gibraltar
Egypt
Oceania
Taiwan
Zimbabwe
Tunisia
Sweden
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Kyrgyzstan
Haiti
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Puerto Rico
Oman
Poland
Guernsey
Cameroon
Colombia
China
Armenia
Czech Republic
Costa Rica
Marshall Islands
Kuwait
Malta
Luxembourg
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Jamaica
Sri Lanka
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Uganda
Myanmar
Turkey
Uruguay
Seychelles
Moldova
Paraguay
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Portugal
Philippines
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Angola
Europe
Cyprus
Spain
Qatar
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Faroe Islands
Estonia
Bahrain
Bahamas
Jersey
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Lithuania
Cambodia
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does LSK Investment invest in?

LSK Investment invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 45 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does LSK Investment invest in?

LSK Investment typically joins rounds of $1.6M–$14M at Series A, $8.3M–$16M at Series B and $3.2M–$46M at Series C. These are whole funding-round sizes, not LSK Investment's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds LSK Investment took part in.

How do I contact LSK Investment?

Public channels for LSK Investment include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at LSK Investment?

The team at LSK Investment includes Lee Myung-kwon (Managing Director). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
LSK Investment LSK Investment Find emails